Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD2 | P25440 | 10/20 | 0.38 |
| ▸ | BRD4 | O60885 | 8/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 8/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16268422 | 0.90 | CREBBP (0.35) | BRD2BRD4BRD3CREBBP | |
| SCHEMBL16268447 | 0.87 | BRD4 (0.37) | BRD2BRD4SLC5A1SLC5A2CYP19A1 | |
| SCHEMBL16268706 | 0.86 | CREBBP (0.38) | BRD2BRD4SLC5A1SLC5A2CYP19A1 | |
| SCHEMBL15148725 | 0.82 | TP53 (0.39) | SLC5A1SLC5A2CYP19A1S1PR1S1PR3 | |
| SCHEMBL16740431 | 0.82 | BRD4 (0.44) | BRD2BRD4SLC5A1SLC5A2CYP19A1 | |
| SCHEMBL16269055 | 0.81 | BRD4 (0.41) | BRD2BRD4SLC5A1SLC5A2BRD3 | |
| SCHEMBL16740574 | 0.80 | BRD4 (0.43) | BRD2BRD4BRD3S1PR1S1PR3 | |
| SCHEMBL15148339 | 0.80 | S1PR1 (0.42) | SLC5A1SLC5A2S1PR1S1PR3POLB | |
| SCHEMBL15148256 | 0.80 | SLC5A1 (0.39) | SLC5A1SLC5A2CYP19A1S1PR1S1PR3 | |
| SCHEMBL15148297 | 0.80 | KMT2A (0.39) | SLC5A1SLC5A2CYP19A1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412675-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | TPMT, REN, IL5 | BRD2 539/4885BRD4 176/4885SLC5A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.